Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAS) have a 78 % lower risk of death and a 44 % lower risk of serious cardiovascular events compared to those who take other diabetes or weight reduction medication, such as new ones Show research results.
The study – the largest of its kind that was presented today at the 2025 Congress of the European Academy of Dermatology and Venereology (EADV) – also showed that GLP -1RAS significantly reduce the risk of alcohol abuse by 65 % and drug abuse.
Psoriasis is a chronic skin disease, which is affected by 2-3 % of the population and which are not only associated with visible symptoms, but also with a higher risk of heart attack, stroke and psychiatric problems such as depression, anxiety and increased alcohol or drug use. GLP-1RAS, including Semaglutid and Liraglutide, are often used to treat type 2 diabetes and obesity. However, these new findings indicate that they can also be of great benefit to psoriasis patients.
The researchers have accessed data from a database with over 110 million patients in the United States. The results of over 6,000 psoriasis patients with diabetes or obesity were compared over a period of two years, including 3,048, which were treated with GLP-1RAS, and 3,048, which received other medications against diabetes or obesity.
After comparing the age, gender and comorbidities, the advantages of GLP-1RAS in all sensitivity analyzes were clear and consistent, with propensity score matching being used to control potential disruptive factors.
Professor Ralf Ludwig, the main author of the study, commented: “Our results indicate that GLP-1 receptor agonists can offer advantages beyond their effects on weight and blood sugar control, especially for cardiovascular and psychiatric results in people with psoriasis. Mediators can inhibit people with psoriasis.
These advantages seemed particularly pronounced in psoriasis patients compared to the corresponding controls, which indicates a possible synergy between systemic inflammation in psoriasis and the mechanisms of GLP-1RAS. The security results corresponded to those of the general population without a significant increase in undesirable effects such as hypoglycemia, nausea or constipation.
“In view of their security profile and the range of the observed advantages, GLP-1RAS could become a preferred treatment for people with psoriasis who also need therapy for diabetes or weight management,” concluded Prof. Ludwig.
View original content:https://www.prnewswire.com/news-releases/eadv-kongress-2025-glp-1ra-medikamente-verringern-das-sterbe–und-herz-kreislauf-risiko-bei-psoriasis-patienten-drastisch-302555435.html